Cadila Healthcare Ltd. v. Swiss Pharma Pvt. Ltd.

In the fiercely competitive pharmaceutical industry, brand names can make or break a product. But what happens when two companies choose names that look and sound remarkably alike? Is structural similarity alone enough to win a passing off case, or does the law demand proof of actual deception? The dispute between Cadila Healthcare and Swiss Pharma offers a masterclass in where the legal line is drawn between coincidence and consumer confusion.

Cadila Healthcare Ltd., an established pharmaceutical company, marketed a medicine under the trademark SPARDAC. Swiss Pharma Pvt. Ltd., a competing pharmaceutical business, brought its own medicine to market under the name SUPERDAC. Cadila took swift legal action, filing a suit alleging that Swiss Pharma was passing off its product as Cadila's by adopting a deceptively similar trademark. The core of Cadila's grievance rested on the phonetic and visual closeness between SPARDAC and SUPERDAC, arguing that this similarity was designed to mislead consumers, chemists, and medical professionals.

Cadila argued that the two trademarks were deceptively similar, contending that the structural and phonetic overlap between SPARDAC and SUPERDAC created a real risk of confusion in the marketplace. They maintained that consumers, particularly those purchasing medication, could easily mistake one product for the other, leading to unfair commercial advantage for Swiss Pharma. Swiss Pharma, on the other hand, countered that the two names were sufficiently distinct and that no actual evidence of deception or confusion existed. The trial court examined the evidence and sided with Swiss Pharma, finding no proof that anyone had actually been misled or confused by the two competing brands. Cadila then escalated the matter to the Gujarat High Court, seeking to overturn this initial ruling.

The Gujarat High Court upheld the trial court's decision in favor of Swiss Pharma. The court concluded that despite the structural resemblance between SPARDAC and SUPERDAC, the two trademarks were not deceptively similar in a legal sense. Critically, the court found no evidence of actual likelihood of confusion among consumers, chemists, or doctors. Without proof that the similarity translated into real-world deception, the passing off claim could not stand. The judgment reinforced a fundamental principle of trademark law: similarity alone is not enough, there must be a demonstrated likelihood of confusion to succeed in a passing off action.

For founders and IP professionals, this case delivers a clear and practical lesson: structural or phonetic similarity between two brand names is not, by itself, sufficient grounds for a passing off claim. To succeed, you must demonstrate that the similarity actually creates a likelihood of confusion in the minds of the relevant audience, whether that's end consumers, retailers, or prescribing professionals. Before launching a new product, invest in thorough trademark searches and consider not just how a name looks on paper, but how it functions in the real marketplace. And if you find yourself on the defending end of a passing off suit, remember that the burden of proving actual deception lies with the claimant, not you.